Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Jun;40(6):819-23.
doi: 10.1007/s00259-013-2374-2.

PSMA as a target for radiolabelled small molecules

Matthias Eder, Michael Eisenhut, John Babich, Uwe Haberkorn
Editorial

PSMA as a target for radiolabelled small molecules

Matthias Eder et al. Eur J Nucl Med Mol Imaging. 2013 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Maximum intensity projection image of a PET scan performed on day 5 after administration of 124I-MIP-1095 shows multiple lesions in bones and lymph nodes, and also accumulation in the salivary and lacrimal glands. b Whole-body scan 7 days after administration of 5 GBq 131I-MIP-1466 in the same patient
Fig. 2
Fig. 2
PET images in the same patient using the 68Ga-labelled PSMA inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (a) and 18F-fluoroethylcholine (b). The scan with the PSMA ligand shows significantly more lesions than the fluoroethylcholine scan in which only one metastasis is seen
Fig. 3
Fig. 3
SPECT/CT fusion images in a patient with biopsy-proven PCa and a PSA level of 8.5 ng/mL. The images were acquired 2 weeks prior to surgery. The scan was performed 4 h after injection of 740 MBq 99mTc-MIP-1404. Bilateral disease is visualized and was confirmed on pathology with one lesion showing a Gleason score of 7 (green arrow) and the other a Gleason score of 6 (red arrow)
See this image and copyright information in PMC

References

    1. National Cancer Institute, Surveillance Epidemiology and End Results. SEER stat fact sheets: prostate. Available from: http://seer.cancer.gov/statfacts/html/prost.html.
    1. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436–445. doi: 10.1056/NEJMoa1209978. - DOI - PMC - PubMed
    1. Pinto F, Totaro A, Palermo G, Calarco A, Sacco E, D’Addessi A, et al. Imaging in prostate cancer staging: present role and future perspectives. Urol Int. 2012;88:125–136. doi: 10.1159/000335205. - DOI - PubMed
    1. Klotz L. Cancer overdiagnosis and overtreatment. Curr Opin Urol. 2012;22:203–209. doi: 10.1097/MOU.0b013e32835259aa. - DOI - PubMed
    1. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28:2810–2816. doi: 10.1200/JCO.2009.25.7311. - DOI - PubMed

Publication types